PubMed Health⌕ Search

Biomedical subjects

A Aharon

Publications and source records attributed to A Aharon.

22 records · Page 2Linked to original sources

Identification of photoproducts liberated by in vitro argon laser irradiation of atherosclerotic plaque, calcified cardiac valves and myocardium.

To determine how laser light effects alterations in cardiovascular tissue, photoproducts liberated as the result of argon laser irradiation of atherosclerotic plaque, myocardium and calcified aortic valve leaflets were analyzed by gas chromatography, gas chromatography-mass spectrometry and absorbance spectroscopy. The products formed in gas phase are those expected when proteins and porphyrins are pyrolyzed--light hydrocarbon fragments, carbon monoxide and water vapor. The laser-generated products dissolved in solution are those expected when a protein chain or porphyrin ring is degraded in a thermal reaction, namely protein fragments and nitrogen heterocyclic ring fragments. These photoproducts are those typical of combustion or thermal degradation, and indicate that the fundamental nature of laser irradiation of coronary plaque, myocardium and calcified valve leaflets is thermal rather than photochemical. Thermal degradation of myocardium is more extensive than thermal degradation of atherosclerotic arteries or calcified valves because the red hue of myoglobin-containing myocardium enhances the absorption of the blue-green argon laser light. In contrast, the yellow-white hue of both atherosclerotic plaque and calcified aortic valve leaflets allows less complete absorbance of the argon laser light, leading to a lesser amount of converted heat and, therefore, less complete thermal degradation.

Arteriosclerosis↗

A comparison of distribution between simultaneously or sequentially delivered antegrade/retrograde blood cardioplegia.

UNLABELLED: Commercially available cardioplegia delivery systems now allow for antegrade (aortic root, coronary ostia, saphenous vein graft) perfusion to occur either sequentially or simultaneous with retrograde (coronary sinus) perfusion. This study was designed to compare the total flow and local distribution of sequential versus simultaneous antegrade/retrograde cardioplegia delivery. METHODS: Explanted human hearts diagnosed with idiopathic cardiomyopathy underwent a cold cardioplegic arrest and bicaval cardiectomy. Thirty-seven degree centigrade blood cardioplegia containing colored microspheres was then delivered antegrade (red color) at a pressure of 80 mmHg or retrograde (blue color) at a pressure of 40 mmHg. In the sequential group (n = 6), cardioplegia was delivered antegrade and then retrograde for 2 minutes, respectively. For the simultaneous group (n = 6), cardioplegia was delivered both antegrade and retrograde for 2 minutes. The ventricular myocardium was then sampled at 12 representative sites to determine regional cardioplegic flow. RESULTS: Mean total cardioplegia delivery/minute was 0.69 +/- 0.62 mL/g per minute for sequential cardioplegia, and 0.46 +/- 0.19 mL/g per minute for simultaneous cardioplegia (p > 0.05, NS). At the 12 ventricular sites sampled, mean regional cardioplegic flow (mL/g per min) was in general slightly greater for sequential delivery. However, this was not statistically significant (p > 0.05, NS). CONCLUSION: The data suggest that there may be a slight advantage in total cardioplegia delivery and regional cardioplegia delivery when using sequential rather than simultaneous cardioplegia delivery. However, this difference was not statistically significant and is likely not of clinical significance. Therefore, we would recommend using either sequential or simultaneous antegrade/retrograde cardioplegia based upon whichever technique facilitates the conduct of the individual operation.

Aorta↗

University of Wisconsin solution versus Stanford cardioplegic solution and the development of cardiac allograft vasculopathy.

BACKGROUND: University of Wisconsin (intracellular) solution has been shown to offer some distinct benefits of myocardial preservation over Stanford (extracellular) solution, including a more rapid functional recovery, improved adenosine triphosphate preservation, and a tendency for less postoperative inotropic agents. However intracellular solutions with high potassium content have been reported to cause a functional if not structural endothelial injury in laboratory experiments. METHODS: Because of this information we retrospectively viewed our follow-up angiographic data for the development of the cardiac allograft vasculopathy in a consecutive series of 195 heart transplant recipients. These patients were treated in identical fashion, with the same immunosuppression regimen, except for the type of cardioplegia used--Stanford solution (group I n = 95) and University of Wisconsin solution (group II n = 100). RESULTS: With a mean follow-up of 24 months after transplantation, a significant difference was seen in the development of cardiac allograft vasculopathy in group II (22%) versus group I (14%, p < 0.03). Although significant differences were observed with univariate analysis with respect to donor age and ischemic time favoring group I and with multivariate statistical analysis with respect to overall rejections favoring group II, the only significant variable for the difference in the development of allograft vasculopathy was University of Wisconsin cardioplegic solution (p < 0.003). A subgroup of 30 patients previously randomized for a functional study comparing the two cardioplegic agents showed a tendency for statistical significance with a freedom from allograft vasculopathy of 93% in group I, as compared with 83% in group II, after 13 months follow-up (p = 0.09). The overall probability of being free of vasculopathy at 24 months was 86% for group I and 70% for group II. CONCLUSIONS: The data support the conclusion that University of Wisconsin intracellular solution is associated with an increased incidence of vasculopathy versus Stanford solution and warrants investigation for modification of this preservation agent in heart transplantation.

Adenosine↗